Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis

BACKGROUND: Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. METHODS: Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. RESULTS: Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0-12.0) and 14.0 days (interquartile range, 10.0-20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33-5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33-4.48]), female sex (HR, 1.78 [95% CI, 1.00-3.16]), and age (HR per year, 1.04 [95% CI, 1.00-1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64-4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76-3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20-3.01]), and age (HR per year, 1.06 [95% CI, 1.03-1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. CONCLUSIONS: In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02329327.

Authors

Institutions

Publication Details

Journal
Stroke
Published
2026-11-13
DOI
https://doi.org/10.1161/strokeaha.125.053981
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis

Saskia Middeldorp, Alexander Thomas Cohen, Jan Beyer‐Westendorf, Jonathan M. Coutinho et al.
3 links
Stroke
Atrial Fibrillation Management and Outcomes
article

Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis

Saskia Middeldorp, Alexander Thomas Cohen, Jan Beyer‐Westendorf, Jonathan M. Coutinho, Charles Michael Gibson, Sven Poli, Cecilia Falkenberg, Johannes Sebastian Mutzenbach, Else Charlotte Sandset, Cameron D. Joyner, Georgios K. Tsivgoulis, Andrew M. Demchuk, Robin Lemmens, Pierre Amarenco, David Tanné, Truman John Milling, Hanne Christensen, Rohit Narayan, Roland C. Veltkamp, Ashkan Shoamanesh, Raisa Kurlyandskaya, Mukul Sharma, Peter B. Verhamme, Robert Mikulík, Bernhard Ganser, Danilo Toni, Anna Członkowska, Dániel Bereczki, Arne G. Lindgren, David Julian Seiffge, Per Ladenvall, Mark Andrew Crowther, Nele Bubel, Deborah M. Siegal, G E Raskob, Alexandra Bernegger, Risto O. Roine, John W. Eikelboom, Ursula Leitner, Melanie Baumgartinger, Robin Hart, Robinson T.G., H.R. Büller, Mikael Knutsson, ALEKSANDRA L LINDGREN, S. Connolly, D. George Wyse, Carlos Alberto Molina, H. Kohlfurst, T. Tatlisumak, S. Pikija, E. Lenzenweger, V. Tedim-Cruz, M. Schonfelder, L. Ritscher, I. Krehan, J. Cairns, A. Rohracher, G. Tsvigoulis, M. Gaugg, I. Oberdorfer, W. Lang, M. Komposch, J. Ferrari, A. Lindner, G. Pilz, B. Ramprecht, A. Schiefecker, A. Schmidt, B. Pfausler, J. Mente, R. Beer, Lizhen Xu, E. Sandset, S. Kasner, E. Hoefner, K. Mahaffey, M. Prins, C. Hecker, K. Sorre, C. Stadler, J.H. Alexander, D. Seiffge, R. Roine, S. Krebs, D. Garcia, L. Kellermair, C.B. Sorschag, V. Rass, R. Helbok, A. Pramsohler, A. Kuschnig, J. Coutinho, T. Cook, H. Novak, F. Gruber, C. Roesler, M. Konrad, S. Eger
article en

Abstract

BACKGROUND: Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. METHODS: Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. RESULTS: Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0-12.0) and 14.0 days (interquartile range, 10.0-20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33-5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33-4.48]), female sex (HR, 1.78 [95% CI, 1.00-3.16]), and age (HR per year, 1.04 [95% CI, 1.00-1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64-4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76-3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20-3.01]), and age (HR per year, 1.06 [95% CI, 1.03-1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. CONCLUSIONS: In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02329327.

Stroke
Semmelweis University (HU), University of Bern (CH), Oslo University Hospital (NO), St Thomas' Hospital (GB), Harvard University (US), Radboud University Nijmegen (NL), University of Ottawa (CA), University of Calgary (CA), Technion – Israel Institute of Technology (IL), King's College London (GB), Lund University (SE), Guy's and St Thomas' NHS Foundation Trust (GB), National and Kapodistrian University of Athens (GR), Stiftelsen Norsk Luftambulanse (NO), Universitair Ziekenhuis Leuven (BE), University Hospital of Bern (CH), Rambam Health Care Campus (IL), Bispebjerg Hospital (DK), Turku University Hospital (FI), Copenhagen University Hospital (DK), Population Health Research Institute (CA), Radboud University Medical Center (NL), NIHR Imperial Biomedical Research Centre (GB), Vall d'Hebron Hospital Universitari (ES), Skåne University Hospital (SE), University General Hospital Attikon (GR), Hertie Institute for Clinical Brain Research (DE), AstraZeneca (Sweden) (SE), Hôpital Bichat-Claude-Bernard (FR), Alfried Krupp Hospital (DE), Amsterdam University Medical Centers (NL), Institute of Psychiatry and Neurology (PL), University Hospital Carl Gustav Carus (DE), Hotchkiss Brain Institute (CA), University of Houston (US), Imperial College London (GB), Hamilton Health Sciences (CA), University of Tübingen (DE), Sapienza University of Rome (IT), University of Amsterdam (NL), McMaster University (CA), KU Leuven (BE)
Good health and well-being
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon